Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Insmed To Participate in Five September Conferences

INSM

BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:

  • Citi's 16th Annual BioPharma Virtual Conference on September 8, 2021 at 9:45 a.m. ET in a fireside chat
  • The Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 3:30 p.m. ET in a fireside chat
  • The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 a.m. ET in a fireside chat available for on-demand viewing
  • SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event on September 22, 2021 in 1x1 investor meetings
  • The Cantor Fitzgerald Virtual Global Healthcare Conference on September 27, 2021 at 8:00 a.m. ET in a fireside chat

Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the respective presentation dates.

About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

(PRNewsfoto/Insmed Incorporated)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-participate-in-five-september-conferences-301366701.html

SOURCE Insmed Incorporated